ImmuCell Corp. (ICCC)
10.25
-0.19
(-1.82%)
USD |
NASDAQ |
Oct 23, 16:00
10.25
0.00 (0.00%)
After-Hours: 20:00
ImmuCell Enterprise Value : 96.68M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 96.68M |
| October 22, 2026 | 98.41M |
| October 21, 2026 | 99.13M |
| October 20, 2026 | 98.50M |
| October 19, 2026 | 99.04M |
| October 16, 2026 | 101.22M |
| October 15, 2026 | 99.50M |
| October 14, 2026 | 101.22M |
| October 13, 2026 | 101.58M |
| October 12, 2026 | 90.78M |
| October 09, 2026 | 92.59M |
| October 08, 2026 | 92.14M |
| October 07, 2026 | 91.59M |
| October 06, 2026 | 94.14M |
| October 05, 2026 | 92.14M |
| October 02, 2026 | 92.14M |
| October 01, 2026 | 90.78M |
| September 30, 2026 | 92.59M |
| September 29, 2026 | 93.86M |
| September 28, 2026 | 93.32M |
| September 25, 2026 | 93.73M |
| September 24, 2026 | 94.14M |
| September 23, 2026 | 94.32M |
| September 22, 2026 | 94.32M |
| September 21, 2026 | 95.59M |
| Date | Value |
|---|---|
| September 18, 2026 | 93.96M |
| September 17, 2026 | 94.23M |
| September 16, 2026 | 90.87M |
| September 15, 2026 | 90.59M |
| September 14, 2026 | 91.78M |
| September 11, 2026 | 93.05M |
| September 10, 2026 | 93.64M |
| September 09, 2026 | 93.59M |
| September 08, 2026 | 92.96M |
| September 04, 2026 | 93.50M |
| September 03, 2026 | 94.41M |
| September 02, 2026 | 94.41M |
| September 01, 2026 | 93.68M |
| August 31, 2026 | 92.50M |
| August 28, 2026 | 93.86M |
| August 27, 2026 | 94.59M |
| August 26, 2026 | 94.59M |
| August 25, 2026 | 92.96M |
| August 24, 2026 | 92.96M |
| August 21, 2026 | 94.95M |
| August 20, 2026 | 95.23M |
| August 19, 2026 | 95.59M |
| August 18, 2026 | 92.23M |
| August 17, 2026 | 91.68M |
| August 14, 2026 | 94.86M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
| Vericel Corp. | 2.108B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.835M |
| Revenue (Quarterly) | 7.186M |
| Total Expenses (Quarterly) | 5.352M |
| EPS Diluted (Quarterly) | 0.1996 |
| Gross Profit Margin (Quarterly) | 33.92% |
| Profit Margin (Quarterly) | 25.53% |
| Earnings Yield | 0.82% |
| Operating Earnings Yield | 2.00% |
| Normalized Earnings Yield | 1.345 |